Drilldown: Medicines

Other values:

Search

None (70) · Anafranil (1) · Aurorix (1) · Clozaril (Novartis, original brand; 25 mg and 100 mg tablets); FazaClo (orally disintegrating tablets, 12.5/25/100/150/200 mg); Versacloz (oral suspension 50 mg/mL); multiple generics. All clozapine products are subject to the same REMS monitoring requirements. (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Irreversible non-selective MAO inhibitor (3) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Contains LSA (2) · Contains mescaline (2) · Serotonin–norepinephrine reuptake inhibitor (2)

Other values:

Search

None (89) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1)

None (88) · 12.5 mg PO once or twice daily. Titrate gradually: 25-50 mg/day increments every 1-2 days as tolerated. Target dose 300-450 mg/day in divided doses (BID or TID). Most patients stabilize between 200-600 mg/day. Therapeutic plasma level guide: target trough clozapine ≥350 ng/mL. (1) · 25 mg (1)

None (88) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Clozaril 25 mg and 100 mg tablets; FazaClo orally disintegrating tablets (12.5/25/100/150/200 mg); Versacloz oral suspension 50 mg/mL. All brands subject to identical REMS ANC monitoring requirements. Generic tablets widely available. (1)

None (88) · 200 mg/d (1) · 900 mg/day (split into BID or TID dosing). Clinical practice rarely exceeds 600 mg/day; seizure risk increases substantially above 600 mg/day and requires consideration of prophylactic anticonvulsant.'"`UNIQ--ref-0000004A-QINU`"' (1)

None (86) · Oral (3) · Oral only. No parenteral formulation (a major limitation in acute agitation requiring rapid tranquilization). (1)

None (86) · 30–60 minutes (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · Oral peak plasma 2.5 hours. Clinical antipsychotic response typically emerges over weeks with continued titration; full response assessment requires 3-6 months at adequate therapeutic levels. (1)

None (86) · 8–12 hours (1) · Chronic daily dosing (1) · Due to the half-life of 12 hours (wide range), dosing is BID or TID. Once-daily dosing produces higher peak/trough fluctuations and is generally not used except for a single end-of-day dose in stable patients. (1) · Long (1)

None (87) · 3–5 hours (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (86) · 70–90% (oral) (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Approximately 50-60% (oral; subject to first-pass metabolism); food does not significantly affect absorption.'"`UNIQ--ref-0000004C-QINU`"' (1) · ~50% (highly variable) (1)

None (87) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Not established (1)

None (87) · Rx-only (1) · Rx-only in US (1) · Schedule I (United States) (1)